Market Performance Overview
During a 24‑hour trading window that concluded at 10:39 p.m. Central Europe on Friday, 23 November, Artivion Inc. (AORT) advanced 4.67 %. The stock is presently listed at approximately USD 23.30 on major exchanges, with a total supply of 48.8 million shares. These figures translate into a market capitalisation of USD 1.1 billion. In the past 24 hours, roughly USD 13 million worth of Artivion shares changed hands, a modest volume relative to its market size.
Relative to its own historical performance, the share price has risen 1.87 % since the close of the previous month. Over a 200‑day horizon, the simple moving average sits at USD 30.01, underscoring that the current price lies well below the long‑term mean. The all‑time high for the past year—USD 48.25 on 17 December 2025—remains out of reach, while the 52‑week low of USD 19.16 was recorded on 8 May 2026, indicating a healthy range of volatility for the company’s equity.
Upcoming Earnings Release
Artivion Inc. has confirmed that its third‑quarter 2026 financial results will be disclosed after market close on Thursday, 5 November 2026. Investors can anticipate a comprehensive earnings presentation that includes:
- Teleconference call and live webcast at 4:30 p.m. Eastern Time
- Q&A session moderated by Chief Executive Officer Pat Mackin
- Replay of the event to be released a few hours later
All materials—webcast, replay, and the accompanying press release—will be accessible via Artivion’s official website. As a medical‑device specialist focused on aortic disease solutions, the company remains committed to advancing innovations that facilitate cardiac and vascular surgery worldwide.
Peer Activity Snapshot
The performance of several peer companies over the same 24‑hour period offers context for Artivion’s recent movement:
| Company | Ticker | 24‑h Change | Current Price | Market Cap | P/E |
|---|---|---|---|---|---|
| Napco Security | NSSC | +3.65 % | USD 38.82 | USD 1.3 bn | 31.04 |
| Taysha Gene Therapies | TSHA | +0.24 % | USD 3.96 | USD 1.3 bn | – |
| RPC | RES | –4.75 % | USD 6.25 | USD 1.3 bn | 63.45 |
| Universal Insurance | UVE | +1.40 % | USD 48.84 | USD 1.3 bn | 6.29 |
| Damora Therapeutics | DMRA | +4.16 % | USD 21.09 | USD 1.3 bn | – |
While the peer group displays a mix of gains and declines, Artivion’s 4.67 % rise positions it favorably against the broader cohort, particularly when considering the company’s long‑term upside potential.
Recent Corporate Developments
Artivion Inc.
Artivion’s core mission revolves around delivering sophisticated, user‑friendly solutions to the complex challenges of cardiac and vascular surgeons treating aortic disease. Its portfolio includes:
- Aortic stents and stent grafts
- Prosthetic heart valves
- Cryopreserved cardiac and vascular allografts
- Surgical sealants
Since its initial public offering in 1993, Artivion has maintained a presence on the New York Stock Exchange, reinforcing its standing as a seasoned player in the medical‑device arena.
Stewart Information Services
The company announced its third‑quarter 2026 results on 21 October. Key highlights include:
- Revenue growth relative to the same period a year earlier
- Declining net income and earnings per share, attributable to tighter operating margins
- Anticipated industry headwinds for the coming year
- Growth in real‑estate solutions, driven by the MCS acquisition and expanded credit valuation services
- Operating cash flow falling year‑over‑year, with a focus on disciplined cost management
Universal Insurance Holdings, Inc.
In its filing dated 22 October 2026, Universal Insurance reported:
- Higher operating performance with increased revenues and operating income
- Growth in net premiums earned from expanded direct premiums and a new reinsurance program
- Improved underwriting ratios (combined ratio ≈ 91 %)
- Dividend declaration of 16 cents per share
- A modest share repurchase program and a continued emphasis on capital discipline
Damora Therapeutics Inc.
Damora’s third‑quarter results reflected:
- A modest rise in net asset value alongside a similar share‑price appreciation
- Portfolio performance buoyed by U.S. drug approvals and acquisitions from Vertex Pharmaceuticals and GSK
- Reinvestment of proceeds and a balanced addition/divestiture strategy (12 new positions, 8 divested)
- A narrowing discount to net asset value, indicating a tighter valuation gap
- Continued focus on its AI‑driven investment framework that merges scientific, clinical, and commercial data
Napco Security
Napco’s performance in the last 24 hours included a 3.65 % increase, reflecting a broader resilience among security‑focused firms.
Conclusion
Artivion Inc. continues to navigate a dynamic market environment, evidenced by its recent 4.67 % rally and a forthcoming earnings release that promises insights into its strategic trajectory. By maintaining a portfolio of advanced aortic‑disease solutions and leveraging its longstanding market presence, the company is poised to deliver value to investors while advancing medical innovation.
